Summary
5.06
0.12
(2.33%)
04/13/2026
Bicycle Therapeutics plc (BCYC)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 2.33 | 1.02 | -6.79 | -24.92 | -40.63 | -24.35 | -81.70 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Strong Sell |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 5.06 | |
| Open | 4.99 | |
| High | 5.09 | |
| Low | 4.89 | |
| Volume | 263,785 | |
| Change | 0.12 | |
| Change % | 2.33 | |
| Avg Volume (20 Days) | 594,323 | |
| Volume/Avg Volume (20 Days) Ratio | 0.44 | |
| 52 Week Range | 4.24 - 9.55 | |
| Price vs 52 Week High | -47.07% | |
| Price vs 52 Week Low | 19.22% | |
| Range | -0.60 | |
| Gap Up/Down | -0.04 | |
Profitibility | ||
| Market Capitalization (Mln) | 449 | |
| Revenue per share | 1.0477 | |
| Net Income per share | -3.1605 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -1.5630 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
04/07 04:59 EST - defenseworld.net
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) CEO Kevin Lee sold 5,967 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total value of $29,297.97. Following the completion of the sale, the...
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) CEO Kevin Lee sold 5,967 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total value of $29,297.97. Following the completion of the sale, the...
04/05 02:35 EST - defenseworld.net
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus rating of "Hold" from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold...
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus rating of "Hold" from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold...
03/24 10:35 EST - zacks.com
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
03/23 10:36 EST - zacks.com
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
03/18 07:00 EST - businesswire.com
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster...
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster...
03/17 07:00 EST - businesswire.com
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and...
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and...
02/14 01:28 EST - defenseworld.net
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold...
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold...
02/03 07:00 EST - businesswire.com
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced leadership transitions for its next phase of...
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced leadership transitions for its next phase of...
01/12 07:00 EST - businesswire.com
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today highlights 2025 accomplishments and strategic priorities...
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today highlights 2025 accomplishments and strategic priorities...
12/26 02:02 EST - defenseworld.net
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Hold” from Brokerages
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating...
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Hold” from Brokerages
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating...
12/16 01:00 EST - businesswire.com
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced it has entered into a 15-year contract...
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced it has entered into a 15-year contract...
12/11 10:00 EST - prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ: BCYC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ: BCYC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
12/01 01:28 EST - defenseworld.net
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received an average recommendation of "Hold" from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold...
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received an average recommendation of "Hold" from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold...
11/18 15:09 EST - newsfilecorp.com
ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Bicycle Therapeutics plc ("Bicycle Therapeutics plc") (NASDAQ: BCYC) concerning possible violations of federal securities laws. On October 31, 2025, RBC Capital...
ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Bicycle Therapeutics plc ("Bicycle Therapeutics plc") (NASDAQ: BCYC) concerning possible violations of federal securities laws. On October 31, 2025, RBC Capital...
11/14 03:15 EST - defenseworld.net
Acadian Asset Management LLC Buys 572,439 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC
Acadian Asset Management LLC grew its stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC) by 454.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 698,501 shares of the company's stock after...
Acadian Asset Management LLC Buys 572,439 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC
Acadian Asset Management LLC grew its stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC) by 454.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 698,501 shares of the company's stock after...
11/12 16:05 EST - businesswire.com
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside...
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside...
10/30 07:00 EST - businesswire.com
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended...
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended...
10/15 08:36 EST - seekingalpha.com
Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn
Bicycle Therapeutics (BCYC) remains a compelling investment, trading below cash value despite promising early data for its lead asset, zelenectide pevedotin. Zelenectide pevedotin shows comparable efficacy to enfortumab vedotin in urothelial cancer, with manageable toxicity and ongoing expansion...
Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn
Bicycle Therapeutics (BCYC) remains a compelling investment, trading below cash value despite promising early data for its lead asset, zelenectide pevedotin. Zelenectide pevedotin shows comparable efficacy to enfortumab vedotin in urothelial cancer, with manageable toxicity and ongoing expansion...
Market News
×
Loading news…